Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Baxter International faces a fundamental downturn after weak Q4 results and a dismal FY 2026 guide, prompting a hold rating downgrade. BAX trades at a very cheap valuation, but persistent margin compression, debt risks, and repeated earnings disappointments overshadow near-term recovery prospects. Despite some growth in Advanced Surgery and new connected care offerings, operational efficiency and profitability remain under severe pressure.
Baxter International misses Q4 EPS estimates as margins shrink, even as revenues top forecasts; shares slide 12.5% on weak 2026 guidance.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Andrew Hider CEO | XBER Exchange | US0718131099 ISIN |
| US Country | 38,000 Employees | 27 Feb 2026 Last Dividend | 1 Jul 2015 Last Split | 27 Oct 1981 IPO Date |
Baxter International Inc. is a global healthcare company with a history dating back to 1931. With its headquarters in Deerfield, Illinois, Baxter specializes in the development and distribution of a wide range of healthcare products aimed at enhancing the health and well-being of people around the world. The company's operations are segmented into four key areas: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. These segments allow Baxter to serve a diverse range of healthcare needs, from critical care to chronic disease management. Baxter's commitment to innovation and quality is evident in its extensive product portfolio and its global presence, selling products in approximately 100 countries through a combination of direct sales force and distributors, including drug wholesalers and specialty pharmacy providers. The company's collaborative efforts, such as agreements with Celerity Pharmaceutical, LLC, and Miromatrix Medical Inc., underscore its dedication to advancing healthcare solutions.
These are critical for patient hydration, medication delivery, and various forms of therapy in clinical settings.
Baxter offers advanced infusion systems and devices that facilitate the safe and precise delivery of IV medications and therapies.
Designed for patients who cannot eat or absorb nutrients through their digestive system, these therapies provide vital nutrition intravenously.
The company supplies a range of generic injectables, including essential drugs for acute care settings.
These products are utilized to control bleeding and promote healing in surgical procedures.
Baxter provides state-of-the-art surgical equipment, including surgical video technologies and precision positioning devices, to enhance surgical efficiency and outcomes.
These systems are designed to improve patient comfort and monitoring capabilities in healthcare settings.
Baxter offers technologies for continuous monitoring and diagnosis of patients, aiding in timely and accurate healthcare delivery.
Devices designed to assist with breathing disorders and respiratory health management.
Providing a comprehensive suite of dialysis therapies and services, including peritoneal dialysis (PD) and hemodialysis (HD), Baxter supports patients with chronic kidney failure.
These products are designed to prevent post-surgical adhesions, enhancing patient recovery and comfort.
Baxter offers specialized compounding services, allowing for customized medication formulations to meet unique patient needs.
Offering a range of inhaled anesthesia products, Baxter supports anesthesiologists in providing safe and effective sedation for surgical procedures.